Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines

Abstract

Provided herein are interleukin-13 receptor α2 peptide-based brain cancer vaccines and methods for treating and vaccinating against brain cancer comprising administering to patients in need thereof interleukin-13 receptor α2 peptide-based brain cancer vaccines. Also provided herein are regimens comprising interleukin-13 receptor α2 peptides and at least one additional peptide and/or immunostimulant.

We claim: 
     
         1 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, and a WT1 peptide. 
     
     
         2 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, and a survivin peptide. 
     
     
         3 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, YKL-40 peptide, and a GP100 peptide. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, the survivin peptide comprises SEQ ID NO:7, and the WT1 peptide comprises SEQ ID NO:8. 
     
     
         5 . The pharmaceutical composition of  claim 2 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, and the survivin peptide comprises SEQ ID NO:7. 
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the IL-13Rα2 peptide comprises any one of SEQ ID NOs:1-4, the EphA2 peptide comprises SEQ ID NO:6, the YKL-40 peptide comprises SEQ ID NO:10, and the GP100 peptide comprises SEQ ID NO:11. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein one or more of the peptides are loaded on dendritic cells. 
     
     
         8 . The pharmaceutical composition of  claim 1 , further comprising an adjuvant. 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the adjuvant is Montanide ISA-51. 
     
     
         10 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of  claim 1 . 
     
     
         11 . The method of  claim 10 , further comprising administering to the subject a helper T cell epitope. 
     
     
         12 . The method of  claim 11 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140  core peptide. 
     
     
         13 . The method of  claim 10 , further comprising administering to the subject an immune response modifier. 
     
     
         14 . The method of  claim 13 , wherein the immune response modifier is poly-ICLC or imiquimod. 
     
     
         15 . The method of  claim 10 , wherein the subject is human. 
     
     
         16 . The method of  claim 10 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally. 
     
     
         17 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, a WT1 peptide, a helper T cell epitope, and an adjuvant; and (ii) a second pharmaceutical composition comprising an immune response modifier. 
     
     
         18 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, a survivin peptide, a helper T cell epitope, and an adjuvant; and (ii) a second pharmaceutical composition comprising an immune response modifier. 
     
     
         19 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject (i) a first pharmaceutical composition comprising an IL-13Rα2 peptide loaded on a dendritic cell, an EphA2 peptide loaded on a dendritic cell, a YKL-40 peptide loaded on a dendritic cell, a GP100 peptide loaded on a dendritic cell, and a helper T cell epitope; and (ii) a second pharmaceutical composition comprising an immune response modifier. 
     
     
         20 . A pharmaceutical composition comprising an IL-13Rα2 peptide, an EphA2 peptide, and another peptide. 
     
     
         21 . The pharmaceutical composition of  claim 20  in which the other peptide is a survivin peptide. 
     
     
         22 . The pharmaceutical composition of  claim 20  in which the other peptide is a WT1 peptide. 
     
     
         23 . The pharmaceutical composition of  claim 20  in which the other peptide is a YKL-40 peptide. 
     
     
         24 . The pharmaceutical composition of  claim 20  in which the other peptide is a GP100 peptide. 
     
     
         25 . A method of vaccinating a patient against glioma, wherein a composition comprising EphA2 883-891  is introduced into the patient under conditions sufficient for the patient to develop a CTL response. 
     
     
         26 . The pharmaceutical composition of  claim 2 , wherein one or more of the peptides are loaded on dendritic cells. 
     
     
         27 . The phai naceutical composition of  claim 3 , wherein one or more of the peptides are loaded on dendritic cells. 
     
     
         28 . The pharmaceutical composition of  claim 2 , further comprising an adjuvant. 
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein the adjuvant is Montanide ISA-51. 
     
     
         30 . The pharmaceutical composition of  claim 3 , further comprising an adjuvant. 
     
     
         31 . The pharmaceutical composition of  claim 30 , wherein the adjuvant is Montanide ISA-51. 
     
     
         32 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of  claim 2 . 
     
     
         33 . The method of  claim 32 , further comprising administering to the subject a helper T cell epitope. 
     
     
         34 . The method of  claim 33 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140  core peptide. 
     
     
         35 . The method of  claim 32 , further comprising administering to the subject an immune response modifier. 
     
     
         36 . The method of  claim 35 , wherein the immune response modifier is poly-ICLC or imiquimod. 
     
     
         37 . The method of  claim 32 , wherein the subject is human. 
     
     
         38 . The method of  claim 32 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally. 
     
     
         39 . A method for treating, preventing, or managing brain cancer in a subject in need thereof comprising administering to said subject the pharmaceutical composition of  claim 3 . 
     
     
         40 . The method of  claim 39 , further comprising administering to the subject a helper T cell epitope. 
     
     
         41 . The method of  claim 40 , wherein the helper T cell epitope is the PADRE peptide, a Tetanus toxoid peptide, or the HBV 128-140  core peptide. 
     
     
         42 . The method of  claim 39 , further comprising administering to the subject an immune response modifier. 
     
     
         43 . The method of  claim 42 , wherein the immune response modifier is poly-ICLC or imiquimod. 
     
     
         44 . The method of  claim 39 , wherein the subject is human. 
     
     
         45 . The method of  claim 39 , wherein the pharmaceutical composition is administered to the subject subcutaneously or intra-nodally.